Protalix BioTherapeutics (PLX) Free Cash Flow (2010 - 2026)

Protalix BioTherapeutics' Free Cash Flow history runs 17 years deep, the most recent figure standing at $21.3 million for Q1 2026.

• On a quarterly basis, Free Cash Flow rose 487.68% year-over-year to $21.3 million in Q1 2026; TTM through Mar 2026 was $14.4 million, a 773.86% increase from a year earlier, with the FY2025 full-year figure at -$12.4 million, down 267.23% from the prior year.
• Free Cash Flow rose to $21.3 million in Q1 2026 per PLX's latest filing, from $2.9 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $21.3 million in Q1 2026 and bottomed at -$9.3 million in Q3 2022.
• The 5-year median for Free Cash Flow is -$3.3 million (2023), against an average of -$634176.5.
• Across the five-year window, Free Cash Flow slumped 319.42% in 2022 and jumped 487.68% in 2026, its largest moves.
• Year by year, Free Cash Flow stood at -$2.5 million in 2022, then surged by 252.22% to $3.9 million in 2023, then decreased by 8.09% to $3.6 million in 2024, then decreased by 18.79% to $2.9 million in 2025, then soared by 634.25% to $21.3 million in 2026.
• Per Business Quant, the three latest PLX Free Cash Flow figures stand at $21.3 million (Q1 2026), $2.9 million (Q4 2025), and -$4.6 million (Q3 2025).